IDENTIFICATION OF CD8+ CELL ANTI HIV FACTOR
IDENTIFICATION OF CD8+ CELL ANTI HIV FACTOR
批准号:
7369044
负责人:
JAY A LEVY
金额:
$1.89万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-03-01 至 2007-02-28
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Introduction Individuals who have been infected with HIV and remain healthy for over 10 years are considered long-term survivors. These asymptomatic individuals have a strong cell-mediated immune response that suppresses HIV replication. This activity is lost as the infected person advances to disease. The antiviral response is mediated by a secreted CD8+ cell antiviral factor (CAF) which blocks transcription via the HIV promoter. CAF is produced at low levels by CD8+ cells from these healthy infected individuals. The protein appears to be unlike any of the known cytokines, chemokines and human growth factors. CAF identification will most likely be achieved through protein purification and mass spectrometry. Methods CD8+ cells from healthy HIV-infected individuals are grown in culture medium lacking serum and where possible, albumin. Fluids are assayed for antiviral activity by standard procedures in the laboratory. Active fluids are then concentrated and fractionated by various biochemical techniques including ion exchange, chromatography, and by sizing columns Fractions with enriched CAF activity are analyzed by 2-D gel and evaluated by mass spectrometry. Results Thus far, we have been able to show that CAF has a molecular size of about 50 kD. By differential 2D gel analysis, there appears to be at least 20 different spots that are associated with CAF activity. Studies are in progress to analyzed by mass spectrometry. Those protein spots that are unique to CAF-containing fluids will be further evaluated. Discussion By mass spectrometry, we hope to be able to identify the protein (CAF) that mediates this anti-HIV activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterization of a New Anti-HIV Immune Protein
-
批准号:9349402
-
项目类别:
-
资助金额:$23.78万
-
财政年份:2017
-
负责人:JAY A LEVY
-
依托单位:
HIV Cure with CCr5 (-) Human IPS Hematopoietic Stem Cells
-
批准号:8659220
-
项目类别:
-
资助金额:$61.31万
-
财政年份:2014
-
负责人:JAY A LEVY
-
依托单位:
HIV Cure with CCr5 (-) Human IPS Hematopoietic Stem Cells
-
批准号:9052116
-
项目类别:
-
资助金额:$69.77万
-
财政年份:2014
-
负责人:JAY A LEVY
-
依托单位:
HIV cure with CCR5 (-) human IPS hematopoietic stem cells
-
批准号:8470397
-
项目类别:
-
资助金额:$51.82万
-
财政年份:2012
-
负责人:JAY A LEVY
-
依托单位:
Protection from HIV Infection in Intravenous Drug Users
-
批准号:8012878
-
项目类别:
-
资助金额:$25.53万
-
财政年份:2010
-
负责人:JAY A LEVY
-
依托单位:
Protection from HIV Infection in Intravenous Drug Users
-
批准号:8100171
-
项目类别:
-
资助金额:$19.58万
-
财政年份:2010
-
负责人:JAY A LEVY
-
依托单位:
Role of Innate Immunity in Controlling HIV Infection
-
批准号:7894208
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2009
-
负责人:JAY A LEVY
-
依托单位:
IDENTIFICATION OF CD8+ CELL ANTI HIV FACTOR
-
批准号:7724166
-
项目类别:
-
资助金额:$1.15万
-
财政年份:2008
-
负责人:JAY A LEVY
-
依托单位:
IDENTIFICATION OF CD8+ CELL ANTI HIV FACTOR
-
批准号:7601815
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2007
-
负责人:JAY A LEVY
-
依托单位:
IDENTIFICATION OF CD8+ CELL ANTI HIV FACTOR
-
批准号:7180932
-
项目类别:
-
资助金额:$2.7万
-
财政年份:2005
-
负责人:JAY A LEVY
-
依托单位:
IDENTIFICATION OF CD8+ CELL ANTI HIV FACTOR
-
批准号:6976620
-
项目类别:
-
资助金额:$3.89万
-
财政年份:2004
-
负责人:JAY A LEVY
-
依托单位:
Project 3 - MBSR & the Immune System in Early HIV Infection
-
批准号:6884431
-
项目类别:
-
资助金额:$17.85万
-
财政年份:2004
-
负责人:JAY A LEVY
-
依托单位:
Role of Innate Immunity in Controlling HIV Infection
-
批准号:6837659
-
项目类别:
-
资助金额:$63.98万
-
财政年份:2003
-
负责人:JAY A LEVY
-
依托单位:
Role of Innate Immunity in Controlling HIV Infection
-
批准号:7496465
-
项目类别:
-
资助金额:$54.28万
-
财政年份:2003
-
负责人:JAY A LEVY
-
依托单位:
Role of Innate Immunity in Controlling HIV Infection
-
批准号:6770071
-
项目类别:
-
资助金额:$62.12万
-
财政年份:2003
-
负责人:JAY A LEVY
-
依托单位:
Role of Innate Immunity in Controlling HIV Infection
-
批准号:7787097
-
项目类别:
-
资助金额:$72.15万
-
财政年份:2003
-
负责人:JAY A LEVY
-
依托单位:
20Years of HIV Research: From Discovery to Understanding
-
批准号:6571328
-
项目类别:
-
资助金额:$1.2万
-
财政年份:2003
-
负责人:JAY A LEVY
-
依托单位:
Role of Innate Immunity in Controlling HIV Infection
-
批准号:7628613
-
项目类别:
-
资助金额:$37.89万
-
财政年份:2003
-
负责人:JAY A LEVY
-
依托单位:
Role of Innate Immunity in Controlling HIV Infection
-
批准号:7338224
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2003
-
负责人:JAY A LEVY
-
依托单位:
Role of Innate Immunity in Controlling HIV Infection
-
批准号:7338413
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2003
-
负责人:JAY A LEVY
-
依托单位:
国内基金
海外基金
登录
查看更多内容
糖脂代谢重塑型金属多酚纳米药物促进CD8+ T细胞活化浸润增效PD-1抗体治疗三阴性乳腺癌的研究
-
批准号:2026JJ50635
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘芙蓉
-
依托单位:
前列腺癌CD8+ T细胞雄激素受体表达介导内分泌治疗耐药的机制研究
-
批准号:JCZRLH202601667
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
Leptin通过调控MxA表达促进CD8+ T细胞活化参与白癜风发生发展的作用机制研究
-
批准号:2026JJ81680
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张慧明
-
依托单位:
CD8+ T细胞衰老的代谢调控研究
-
批准号:JCZRQNA202600019
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
核B7-H3调控DKK4介导的CD8+ T细胞耗竭影响结直肠癌远处转移的机制研究
-
批准号:JCZRQNB202600082
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
“增强型”铜死亡纳米药物改善CD8+ T细胞耗竭用于腺导管腺癌免疫治疗的研究
-
批准号:JCZRLH202600099
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
肠道菌群来源的色氨酸代谢物通过芳香烃受体(AhR)调控NMO中枢CD8+ T细胞浸润的机制研究
-
批准号:2026JJ80630
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:周娟
-
依托单位:
长链非编码RNA Malat1通过PTEN/TCF-1促进记忆CD8+ T细胞分化的机
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:李保华
-
依托单位:
MHC-E限制性CD8+调节性T细胞抑制抗肿
瘤免疫反应的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:王蕾
-
依托单位:
细胞凋亡抑制蛋白2通过激活PPAR通路促进黑色素瘤中CD8+ T细胞脂肪酸代谢及抗肿瘤效应的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:孙嘉政
-
依托单位: